Enact Holdings, Inc.
US ˙ NasdaqGS ˙ US29249E1091

Introduction

This page provides a comprehensive analysis of the known insider trading history of Tamar D Howson. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Tamar D Howson has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CUE / Cue Biopharma, Inc. Director 10,000
US:MEIP / MEI Pharma, Inc. Director 50,000
US:IMUX / Immunic, Inc. Director 10,000
US:ONVO / Organovo Holdings, Inc. Director 45,550
US:CTRV / Contravir Pharmaceuticals Inc Director 80,000
US:OXGN / OXiGENE, Inc. Director 77,996
US:ACT / Enact Holdings, Inc. Director 1,539
US:IDIX / Idenix Pharmaceuticals Inc Director 0
Director 0
US:ARDM / Aradigm Corp. Director 140,000
AR:BMY / Bristol-Myers Squibb Company - Depositary Receipt (Common Stock) SVP, Corp & Bus Development 60,084
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Tamar D Howson. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACT / Enact Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACT / Enact Holdings, Inc. Insider Trades
Insider Sales ACT / Enact Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2013-11-06 ACT HOWSON TAMAR D 300 157.3400 300 157.3400 47,202 730

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACT / Enact Holdings, Inc. Insider Trades
Insider Purchases CTRVP / Hepion Pharmaceuticals, Inc. - Preferred Stock - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CTRVP / Hepion Pharmaceuticals, Inc. - Preferred Stock Insider Trades
Insider Sales CTRVP / Hepion Pharmaceuticals, Inc. - Preferred Stock - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CTRVP / Hepion Pharmaceuticals, Inc. - Preferred Stock Insider Trades
Insider Purchases CUE / Cue Biopharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CUE / Cue Biopharma, Inc. Insider Trades
Insider Sales CUE / Cue Biopharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CUE / Cue Biopharma, Inc. Insider Trades
Insider Purchases IMUX / Immunic, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMUX / Immunic, Inc. Insider Trades
Insider Sales IMUX / Immunic, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMUX / Immunic, Inc. Insider Trades
Insider Purchases MEIP / MEI Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MEIP / MEI Pharma, Inc. Insider Trades
Insider Sales MEIP / MEI Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MEIP / MEI Pharma, Inc. Insider Trades
Insider Purchases OTLC / Oncotelic Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OTLC / Oncotelic Therapeutics, Inc. Insider Trades
Insider Sales OTLC / Oncotelic Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OTLC / Oncotelic Therapeutics, Inc. Insider Trades
Insider Purchases VIVS / VivoSim Labs, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VIVS / VivoSim Labs, Inc. Insider Trades
Insider Sales VIVS / VivoSim Labs, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VIVS / VivoSim Labs, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Tamar D Howson as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-01-05 2022-01-03 4 CUE Cue Biopharma, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2021-07-06 2021-07-01 4 MEIP MEI Pharma, Inc.
Stock Option (Right to Buy)
A - Award 50,000 50,000
2021-06-14 2021-06-10 4 IMUX IMMUNIC, INC.
Stock Option
A - Award 10,000 10,000
2021-01-06 2021-01-04 4 CUE Cue Biopharma, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2020-09-18 2020-09-17 4 CUE Cue Biopharma, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2020-07-07 2020-07-02 4 MEIP MEI Pharma, Inc.
Stock Option (Right to Buy)
A - Award 50,000 50,000
2020-07-06 2020-07-02 4 IMUX IMMUNIC, INC.
Stock Option
A - Award 15,000 15,000
2019-10-15 2019-10-11 4 IMUX IMMUNIC, INC.
Stock Option
A - Award 29,959 29,959
2019-07-03 2019-07-01 4 MEIP MEI Pharma, Inc.
Stock Option (Right to Buy)
A - Award 60,000 60,000
2019-07-03 3 MEIP MEI Pharma, Inc.
Common Stock
0
2018-07-30 2018-07-26 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 45,500 45,550 91,000.00
2017-08-28 2017-08-24 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 42,500 42,500
2017-04-11 2017-04-10 4 CTRV ContraVir Pharmaceuticals, Inc.
Stock Options
A - Award 35,000 80,000 77.78
2016-08-19 2016-08-17 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 18,500 18,500
2016-08-19 2016-08-17 4 ONVO ORGANOVO HOLDINGS, INC.
Common Stock
A - Award 7,500 7,500
2015-08-24 2015-08-20 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 37,000 37,000
2015-05-29 2015-05-28 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 77,996 77,996
2015-03-19 2015-03-17 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
F - Taxes -549 1,539 -26.29 307.51 -168,823 473,258
2014-08-26 2014-08-20 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 31,500 31,500
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -3,333 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-07-07 2014-07-02 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 5,280 5,280
2014-06-06 2014-06-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2014-05-13 2014-05-09 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
A - Award 1,142 2,088 120.72 197.05 225,031 411,440
2014-01-06 2014-01-02 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 4,880 4,880
2013-11-08 2013-11-06 4 ACT Actavis plc
Ordinary Shares
S - Sale 300 946 46.44 157.34 47,202 148,844
2013-10-03 2013-10-01 4 ACT Actavis plc
Ordinary Shares
A - Award 1,246 1,246
2013-10-01 2013-09-30 4 WCRX Warner Chilcott plc
Option to purchase ordinary shares par value $0.01 per share
D - Sale to Issuer -14,680 0 -100.00
2013-10-01 2013-09-30 4 WCRX Warner Chilcott plc
Ordinary shares, par value $0.01 per share
D - Sale to Issuer -4,170 0 -100.00
2013-08-23 2013-08-21 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 30,500 30,500
2013-07-02 2013-07-01 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 5,030 5,030
2013-07-02 2013-07-01 4 OXGN OXIGENE INC
Common Stock, $0.01 par value per share
A - Award 3,703 8,761 73.21
2013-06-10 2013-06-06 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2013-06-07 2013-06-05 4 ONVO ORGANOVO HOLDINGS, INC.
Stock Option (Right to Buy)
A - Award 45,500 45,500
2013-05-09 2013-05-07 4 WCRX Warner Chilcott plc
Option to purchase ordinary shares par value $0.01 per share
A - Award 14,680 14,680
2013-05-09 2013-05-07 4 WCRX Warner Chilcott plc
Ordinary shares, par value $0.01 per share
A - Award 4,170 4,170
2013-01-03 2013-01-02 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 2,570 2,570
2013-01-03 2013-01-02 4 OXGN OXIGENE INC
Common Stock, $0.01 par value per share
A - Award 1,886 5,058 59.46
2012-07-05 2012-07-01 4/A OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 25,200 25,200
2012-07-05 2012-07-01 4/A OXGN OXIGENE INC
Common Stock, $0.01 par value per share
A - Award 18,148 38,060 91.14
2012-07-03 2012-07-02 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 25,200 25,200
2012-07-03 2012-07-02 4 OXGN OXIGENE INC
Common Stock, $0.01 par value per share
A - Award 18,148 38,060 91.14
2012-06-11 2012-06-07 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2012-05-30 2012-05-25 4 ARDM ARADIGM CORP
Stock Option (right to buy)
A - Award 140,000 140,000
2012-05-30 2012-05-25 4 ARDM ARADIGM CORP
Common Stock
A - Award 50,000 132,331 60.73
2012-01-04 2012-01-02 4 OXGN OXIGENE INC
Stock Option (Right to Buy)
A - Award 14,200 14,200
2012-01-04 2012-01-02 4 OXGN OXIGENE INC
Common Stock, $0.01 par value per share
A - Award 10,101 19,912 102.96
2003-09-12 2003-09-10 4 (BMY) BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
A - Award 10,000 60,084 19.97
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)